Glenmark Life Sciences Limited (ALIVUS) AI Stock Analysis

Glenmark Life Sciences Limited

(NSE:ALIVUS)

Select Model

Rating:76.6Outperform

Price Target:INR 1,413.00▼(-2.39% Downside)

Action:reiterated

Date:08/11/26

The score is driven primarily by strong financial performance (rapid FY2026 growth, robust margins, and an exceptionally low-debt balance sheet). Technicals are supportive due to a strong uptrend, but overbought indicators (high RSI/Stoch) temper the rating. Valuation is a moderate drag given the 27.98 P/E and low ~0.36% dividend yield.

Positive Factors

API manufacturing platformThe company operates across API research, process development, scale-up and commercial manufacturing, creating an integrated capability for pharmaceutical customers. This supports repeat supply relationships and can help retain value through product complexity, quality requirements and regulatory expertise.

Negative Factors

Weak free-cash-flow conversionAlthough operating cash flow and free cash flow are positive, free cash flow remains well below reported net income. Continued working-capital or capital-expenditure absorption could limit internally available funds, reduce reinvestment flexibility and make earnings less immediately useful for debt reduction or shareholder returns.

Glenmark Life Sciences Limited (ALIVUS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 180.88B
Dividend Yield: 0.34%
Average Volume (3M): 22.75K
Price to Earnings (P/E): 26.5
Beta (1Y): 1.05
Revenue Growth: 8.19%
EPS Growth: 26.12%
Country: India
Employees: 2,272
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Life Sciences Limited Business Overview & Revenue Model

Company Description

Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, prod...

How the Company Makes Money

Glenmark Life Sciences primarily makes money by selling APIs and intermediates to pharmaceutical companies that use these materials to manufacture finished-dose medicines. Revenue is generated through (1) commercial supply of APIs for generic and bra...

Glenmark Life Sciences Limited Financial Statement Overview

Summary

Strong overall fundamentals: sharp FY2026 revenue acceleration (+114.4% YoY) with healthy profitability (gross margin ~44.6%, net margin ~22.1%) and consistently robust EBIT margins (~28–30%). Balance sheet is exceptionally conservative (debt-to-equity ~0.02) with solid ROE (~17%). Main constraint is cash conversion: free cash flow (~₹2.59B) is well below net income (~0.46x), indicating working-capital/capex absorption despite improvement versus FY2025.

Income Statement

86Very Positive

Balance Sheet

93Very Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2024	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	11.91B	25.52B	22.83B	21.61B	18.85B	15.37B
Gross Profit	5.31B	11.37B	12.43B	11.47B	9.80B	8.47B
EBITDA	3.68B	8.32B	6.86B	6.71B	5.92B	4.84B
Net Income	2.53B	5.64B	4.71B	4.67B	3.52B	3.13B
Balance Sheet
Total Assets	36.38B	39.83B	28.50B	27.02B	19.97B	17.26B
Cash, Cash Equivalents and Short-Term Investments	6.53B	7.83B	3.01B	3.80B	1.40B	307.68M
Total Debt	1.13B	567.71M	171.48M	193.57M	9.33B	210.00K
Total Liabilities	6.23B	6.51B	5.18B	5.64B	12.44B	13.24B
Stockholders Equity	30.15B	33.32B	23.32B	21.38B	7.53B	4.02B
Cash Flow
Free Cash Flow	913.92M	2.59B	2.85B	1.43B	3.20B	1.44B
Operating Cash Flow	1.72B	5.66B	4.14B	3.13B	3.88B	1.95B
Investing Cash Flow	-5.43B	-5.71B	-1.16B	-1.54B	-687.34M	-505.18M
Financing Cash Flow	-44.64M	-641.34M	-2.79B	-3.88B	-2.14B	-1.37B

Glenmark Life Sciences Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price1447.60

Price Trends

50DMA1362.40Positive

100DMA1267.47Positive

200DMA1122.44Positive

Market Momentum

MACD10.08Negative

RSI66.85Neutral

STOCH78.13Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALIVUS, the sentiment is Positive. The current price of 1447.60 is above the 20-day moving average (MA) of 1339.12, above the 50-day MA of 1362.40, and above the 200-day MA of 1122.44, indicating a bullish trend. The MACD of 10.08 indicates Negative momentum. The RSI at 66.85 is Neutral, neither overbought nor oversold. The STOCH value of 78.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALIVUS.

Glenmark Life Sciences Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ALIVUS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ALIVUS	77Outperform	INR 172.84B	26.54	―	0.34%	8.19%	26.12%
IN:DIVISLAB	70Outperform	INR 2.58T	90.23	―	0.30%	16.35%	26.84%
IN:NEULANDLAB	66Neutral	INR 252.76B	50.30	―	0.17%	78.33%	182.61%
IN:GRANULES	64Neutral	INR 208.04B	30.33	―	0.21%	21.75%	36.70%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:LAURUSLABS	54Neutral	INR 1.29T	94.64	―	0.09%	23.03%	95.69%
IN:SOLARA	51Neutral	INR 30.43B	82.27	―	―	27.30%	456.80%

* General Sector Average

Performance Comparison

IN:ALIVUS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ALIVUS	Glenmark Life Sciences Limited	1451.00	548.58	60.79%
IN:DIVISLAB	Divi's Laboratories Limited	9950.00	3179.08	46.95%
IN:GRANULES	Granules India Limited	819.55	253.28	44.73%
IN:LAURUSLABS	Laurus Labs Ltd.	2347.00	1364.93	138.98%
IN:NEULANDLAB	Neuland Laboratories Ltd.	19576.05	2001.99	11.39%
IN:SOLARA	Solara Active Pharma Sciences Ltd.	636.70	19.30	3.13%

Glenmark Life Sciences Limited Corporate Events

Alivus Life Sciences Boosts Capital with ESOP Share Allotment

Jul 30, 2026

Alivus Life Sciences Limited has approved the allotment of 32,000 equity shares with a face value of Rs. 2 each to eligible employees exercising options under its Employee Stock Option Scheme, 2021. This move modestly increases the company’s pa...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 11, 2026

Glenmark Life Sciences Limited AI Stock Analysis